MedPath

Far Infrared Irradiation for Control, Management and Treatment of Amyotrophic Lateral Sclerosis (ALS)

Phase 1
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Radiation: Far infrared radiation
Registration Number
NCT00673140
Lead Sponsor
GAAD Medical Research Institute Inc.
Brief Summary

Amyotrophic Lateral Sclerosis (ALS, sometimes called Lou Gehrig's s Disease, or Maladie de Charcot) is a progressive, usually fatal, neurodegenerative disease caused by the degeneration of motor neurons, the nerve cells in the central nervous system that control voluntary muscle movement.

This study will investigate the use of far infrared radiation for the control, management and treatment of ALS.

Detailed Description

As a motor neuron disease, ALS causes muscle weakness and atrophy throughout the body as both the upper and lower motor neurons degenerate, ceasing to send messages to muscles. Unable to function, the muscles gradually weaken, develop fasciculations (twitches) because of denervation, and eventually atrophy due to that denervation. The patient may ultimately lose the ability to initiate and control all voluntary movement except of the eyes.

Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.

It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have ALS.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
7
Inclusion Criteria
  • Patients with ALS
Exclusion Criteria
  • None

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
1Far Infrared Radiation (5μm to 20μm wavelength)Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
1Far infrared radiationRadiation: Far Infrared Radiation (5μm to 20μm wavelength)
Primary Outcome Measures
NameTimeMethod
Therapy for ALS2 years
Secondary Outcome Measures
NameTimeMethod
Rehabilitation of ALS patients2 Years

Trial Locations

Locations (1)

The Centre for Incurable Diseases

🇨🇦

Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath